<DOC>
	<DOCNO>NCT02151084</DOCNO>
	<brief_summary>This phase II study ( second stage test new drug new drug combination ) see useful two different schedule study drug selumetinib cisplatin gemcitabine compare cisplatin gemticabine alone patient biliary cancer . Selumetinib , oral drug play important role regulation cell growth ( MEK 1/2 inhibitor ) show shrink tumour patient biliary cancer type human cancer . Selumetinib also show shrink tumour give combination cisplatin gemcitabine research study do animal patient biliary tract cancer . Cisplatin gemcitabine intravenous drug work damage DNA tumor cell unable grow divide .</brief_summary>
	<brief_title>A Study Different Dosing Schedules Selumetinib With Cisplatin/Gemcitabine ( CIS/GEM ) Versus CIS/GEM Alone Biliary Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Unresectable , recurrent metastatic , measurable biliary tract cancer gall bladder cancer No prior systemic therapy Performance status 0 , 1 , 2 Age 18 year old Estimated life expectancy &gt; 3 month Adequate hematological , liver , renal function No evidence active uncontrolled infection Capable give write consent Acceptable recovery previous side effect Progressing within 3 6 month receive certain treatment Prior chemotherapy nonresectable metastatic disease MEK inhibitor Progressing within 6 month adjuvant treatment . May receive prior chemotherapy nonresectable/metastatic disease . Prior MEK , RAS , RAF inhibitor history hypersensitivity study drug . Ampullary carcinoma Incomplete recovery previous surgery Undergoing treatment curative intent Prior malignancy could interfere response evaluation Severe uncontrolled systemic disease lab find make undesirable patient participate Any psychiatric disorder likely impact consent Pregnant breastfeeding Patients significant cardiacrelated issue History eyerelated issue . Systemic disease , active infection , bleed diatheses renal transplant , include hep B , hep C HIV Receiving potent inhibitor inducer CYP3A4/5 , CYP2C19 CYP1A2 continue caution</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>randomize</keyword>
	<keyword>selumetinib</keyword>
	<keyword>tablet</keyword>
	<keyword>cisplatin</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>non-resectable</keyword>
	<keyword>recurrent</keyword>
	<keyword>metstatic</keyword>
</DOC>